

00270 PATENT TRADEMARK OFFICE

SEQUENCE LISTING

(1883) 6311 8811 881 881 881 881 881 881

<120> Compositions and Methods Useful for Non-Invasive Delivery of Therapeutic Molecules to the Bloodstream

<130> UPN-N2605

<140> US 09/955,444

<141> 2001-09-17

<150> 60/200,409

<151> 2000-04-28

<150> PCT/US01/13000

<151> 2001-04-23

<160> 18

<170> PatentIn version 3.1

<210> 1

<211> 26

<212> DNA

<213> Artificial sequence

<220>

<223> CLONE/CMV promoter/NheI+

<400> 1

aagctagcta gttattaata gtaatc

26

<210> 2

<211> 28

<212> DNA

<213> Artificial sequence

<220>

<223> CLONE/CMV promoter/PstI-

<400> 2

aactgcagga tctgacggtt cactaaac

28

<210> 3

<211> 26

<212> DNA

<213> Artificial sequence

<220>

<223> CLONE/SV40 intron/Pst+

<400> aactgc	3 agaa gttggtcgtg aggcac	26
<210> <211> <212> <213>	4 30 DNA Artificial sequence	
<220> <223>	CLONE/SV40 intron/NotI-	
<400> aagcgg	4 ccgc ctggacacct gtggagaaag	30
<210> <211> <212> <213>	DNA	
<220> <223>	CLONE/lacZ/NotI+	
<400> 5 aagcggccgc catgaccatg attacggatt c 33		
<210> <211> <212> <213>	DNA	
<220> <223>	CLONE/lacZ/BamHI-	
<400> ttggat	6 cctt atttttgaca ccagac	26
<210> <211> <212> <213>	7 26 DNA Artificial sequence	
<220> <223>	CLONE/WPRE/BamHI+	
<400> aaggat	7 ccaa tcaacctctg gattac	26
<210><211><211><212><212>	8 28 DNA	

<220> <223>	CLONE/WRPRE/Bg1II-				
<400> 8					
	ctcg aagacgcgga agaggccg	28			
.					
10105					
<210> <211>	9 29				
<211>					
	Artificial sequence				
<220>					
<223>	CLONE/BGH pA/Bg1II+				
<400>	9	29			
tttagat	cctg cctcgactgt gccttctag	23			
<210>	10				
<211>	29				
<212>	DNA				
<213>	Artificial sequence				
<220>					
<223>	CLONE/BGH pA/XhoI-				
<400>	10				
	agtc cccagcatgc ctgctattg	29			
aaccogc					
<210>	11 `				
<211>	42				
	DNA				
<213>	Artificial sequence				
<220>					
<223>	CLONE/AAV2rep.cap seemless+				
12201					
<400>	11				
agttact	cctt cttgcttgtt aatcaataaa ccgtttaatt cg	42			
2010 5	10				
<210> <211>	12				
<211>	DNA				
<213>					
12107	valatana woguvee				
<220>					
<223>	CLONE/AAV2rep.cap seemless-				
<400>	12	11			
agttactctt cacctgattt aaatcattta ttgttcaaag atgc 44					
<210>	13				
<211>					

<212>	DNA				
	Artificial sequence				
<220> <22 3 >	CLONE/AAV5 Cap seemless+				
<400>	13				
agttact	cett ccaggtatgt cttttgttga tcaccctcca gattgg	46			
<210>	14				
<211>	45				
<212>					
<213>	Artificial sequence	•			
<220>					
<223>	CLONE/AAV5 Cap seemless-				
<400>	14 cett cagcaattaa aggggteggg taaggtateg ggtte	45			
agctact	cett tagtaattaa aggggteggg taaggtateg ggtto				
<210>	15				
<211>					
	DNA Antificial company				
<213>	Artificial sequence				
<220>					
<223>	CLONE/AAV5/Nhei-Xhoi				
<400>	15				
	gaga ttgctagctc actgcttaca aaaccccctt gcttgag	47			
•					
-010	16				
<210> <211>	16 26				
	DNA				
<213>	Artificial sequence				
	•				
<220>	77 OVE / 2 2 VE / VI				
<223>	CLONE/AAV5/XhoI+				
<400>	16				
ttcacag	gctt acaacatcta caaaac	26			
<210>	17				
<211>	33				
<212>					
<213>	Artificial sequence				
<220×					
<220> <223>	CLONE/eGFP/NotI+				
.220/					
<400>	17				
aaagcg	aaagcggccg ccatggtgag caagggcgag gag 33				

<210> 18
<211> 39
<212> DNA
<213> Artificial sequence
<220>
<223> CLONE/eGFP/HindIII-BamHI<400> 18
aaggatccaa gcttattact tgtacagctc gtccatgcc

39